Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Leukemia, Myeloid, Acute 2Leukemia 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 85fludarabine phosphate 84Peripheral Blood Stem Cell Transplantation 75Cyclophosphamide 69Busulfan 62Mycophenolic Acid 50Cyclosporine 48Tacrolimus 47Etoposide 43Whole-Body Irradiation 41Antilymphocyte Serum 40Methotrexate 39Filgrastim 39Radiotherapy 29Melphalan 24Mitoxantrone 23Daunorubicin 23Idarubicin 21Cord Blood Stem Cell Transplantation 18Methylprednisolone 17Flow Cytometry 17sargramostim 15Granulocyte Colony-Stimulating Factor 15Clofarabine 15Transplantation 14Decitabine 14aldesleukin 12Gemtuzumab 12Thiotepa 11Bortezomib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Congenital Abnormalities × lestaurtinib × Clear all
NCT00469859 2017-03-15

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Children's Oncology Group

Phase 1/2 Completed
14 enrolled 9 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡